1 / 6

Netupitant - Palonosetron Market Expected to Reach $527,187 Mn by 2022

Netupitant Palonosetron Market Report, published by Allied Market Research, was valued at $257,162 million in 2015, and is expected to reach $527,187 million by 2022, growing at a CAGR of 10.8% from 2016 to 2022.<br>

newmarketindustry
Download Presentation

Netupitant - Palonosetron Market Expected to Reach $527,187 Mn by 2022

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Netupitant - Palonosetron Market

  2. Netupitant – Palonosetron FDC market holds a substantial scope for growth globally. The market, which is in its growth stage, however, is anticipated to contribute significantly to the global market within the next six years Netupitant Palonosetron Market Report, published by Allied Market Research, was valued at $257,162 million in 2015, and is expected to reach $527,187 million by 2022, growing at a CAGR of 10.8% from 2016 to 2022. Get Sample Report

  3. Netupitant palonosetron FDC market holds a substantial scope for growth globally. The market is in its growth stage; however, its contribution to the global market is expected to increase significantly within the next six years. High cost is a major limitation to for the growth of the market in developing regions. However, recent innovations, which embed high potential and longer duration of action within the CINV drugs reach a wider segment of audiences.

  4. Numerous players are stepping in the CINV market with innovative products. Emerging technology such as novel drugs discovery and innovation of antiemetic therapy are expected to increase the competition in the near future. Number of people living with cancer reached nearly 14.5 million in 2014, and is expected to rise to 19 million by 2024-approximately 31% increment. Of all the new cases recorded globally, approximately 60% of the cases are identified from Asia, Africa, and the Americas.

  5. KEY FINDINGS OF NETUPITANT - PALONOSETRON MARKET: • North America dominated the netupitantpalonosetron market, and is expected to grow at a CAGR of 9.9%. • Asia-Pacific shows thehighestgrowthrate, and is estimated to grow at a CAGR of 14.7%.

  6. Key players profiled in this report include Acacia Pharma, Helsinn Holding S.A., Heron Therapeutics, Inc., and Eisai Pharmaceutical Pvt Ltd.

More Related